New drug could ease CF constipation in just 4 weeks

NCT ID NCT06810167

Recruiting now Symptom relief Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether tenapanor, a drug already approved for irritable bowel syndrome with constipation, can help people with cystic fibrosis who have constipation. Twenty-five adults will take a 50 mg tablet twice daily for 4 weeks and track their bowel movements and symptoms through questionnaires and diaries. The goal is to see if the drug increases spontaneous bowel movements and improves quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tenapanor
What this could lead to: If it works, this could offer a new treatment option for constipation in people with cystic fibrosis, improving bowel regularity and quality of life.
What could go wrong: This is a small, early-phase study with only 25 participants and no placebo group, so results may not apply broadly. Tenapanor is already approved for IBS-C but has not been tested in CF patients before.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONSTIPATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

constipation disorder cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONSTIPATION CYSTIC FIBROSIS

Contacts and locations

Locations

Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.